Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription 11.05.2020 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Clin Pathol 4 Anticancer Res 2 BJU Int 3 BMC Cancer 1 BMC Urol 1 Cancer 1 Cancer Res 1 Clin Cancer Res 1 Eur J Radiol 9 Eur Urol 1 J Cell Physiol 1 J Clin Oncol 1 J Magn Reson Imaging 2 J Nucl Med 2 J Urol 3 Nat Rev Urol 3 PLoS One 3 Prostate 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. WASHINGTON SL 3RD, Baskin AS, Ameli N, Nguyen HG, et al
   MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
   AJR Am J Roentgenol. 2020 Jan 8:1-5. doi: 10.2214/AJR.19.21559.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. ADDO-TABIRI NO, Chudasama R, Vasudeva R, Leiva O, et al
   Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism.
   Am J Clin Oncol. 2020;43:94-100.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

3. XIAO GQ, Golestani R, Pham H, Sherrod AE, et al
   Stratification of Atypical Intraepithelial Prostatic Lesions Based on Basal Cell and Architectural Patterns.
   Am J Clin Pathol. 2020;153:407-416.
   PubMed         Abstract available
   
   

   
   Anticancer Res

4. ZHANG B, Leech M
   A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
   Anticancer Res. 2020;40:2419-2428.
   PubMed         Abstract available
   
   
5. WANG S, Tailor K, Kwabi-Addo B
   Androgen-induced Epigenetic Profiles of Polycomb and Trithorax Genes in Prostate Cancer Cells.
   Anticancer Res. 2020;40:2559-2565.
   PubMed         Abstract available
   
   
6. HAN Q, Tan Y, Hoffman RM
   Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
   Anticancer Res. 2020;40:2813-2819.
   PubMed         Abstract available
   
   
7. OU YC, Chang KH, Tung MC, Tsai IJ, et al
   Building a Nomogram for Prediction of Prostate Cancer in Patients With Preoperatively Suspected Prostate Cancer.
   Anticancer Res. 2020;40:2995-3002.
   PubMed         Abstract available
   
   

   
   BJU Int

8. JOSHI A, Roberts MJ, Alinezhad S, Williams ED, et al
   Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
   BJU Int. 2020 May 8. doi: 10.1111/bju.15103.
   PubMed         Abstract available
   
   
9. SCHWEN ZR, Mamawala M, Tosoian JJ, Druskin SC, et al
   Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance.
   BJU Int. 2020 May 4. doi: 10.1111/bju.15101.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. MILLER ET, You S, Cadaneanu RM, Kim M, et al
    Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    BMC Cancer. 2020;20:398.
    PubMed         Abstract available
    
    
11. WANG M, Wasserman E, Geyer N, Carroll RM, et al
    Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.
    BMC Cancer. 2020;20:394.
    PubMed         Abstract available
    
    
12. WANG S, Zhou X, Liang C, Bao M, et al
    ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients.
    BMC Cancer. 2020;20:387.
    PubMed         Abstract available
    
    

    
    BMC Urol

13. LI Y, Zhong W, Zhu M, Li M, et al
    miR-185 inhibits prostate cancer angiogenesis induced by the nodal/ALK4 pathway.
    BMC Urol. 2020;20:49.
    PubMed         Abstract available
    
    

    
    Cancer

14. PATEL DN, Howard LE, De Hoedt AM, Amling CL, et al
    Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
    Cancer. 2020 May 6. doi: 10.1002/cncr.32933.
    PubMed         Abstract available
    
    

    
    Cancer Res

15. WAHDAN-ALASWAD RS, Song K, Krebs TL, Shola DTN, et al
    Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling.
    Cancer Res. 2020;80:1902.
    PubMed        
    
    

    
    Clin Cancer Res

16. POSADAS EM, Chi KN, de Wit R, de Jonge MJA, et al
    Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study.
    Clin Cancer Res. 2020 May 4. pii: 1078-0432.CCR-19-3402.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

17. ZHANG W, Mao N, Wang Y, Xie H, et al
    A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients.
    Eur J Radiol. 2020;128:109020.
    PubMed         Abstract available
    
    

    
    Eur Urol

18. RADTKE JP, Hadaschik B
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30246.
    PubMed        
    
    
19. STAVRINIDES V, Giganti F, Trock B, Punwani S, et al
    Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30210.
    PubMed         Abstract available
    
    
20. MARCISCANO AE, Barbieri CE
    CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30239.
    PubMed        
    
    
21. DU J, Liu Y, Yan W
    Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://d
    Eur Urol. 2020 Apr 30. pii: S0302-2838(20)30245.
    PubMed        
    
    
22. HADASCHIK B, Herrmann K
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study.
    Eur Urol. 2020 May 1. pii: S0302-2838(20)30319.
    PubMed        
    
    
23. ALBERTSEN PC
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30249.
    PubMed        
    
    
24. KANAYAMA M, Luo J
    Predictive Biomarkers in Prostate Cancer: Is It Time To Go "All In" on Liquid Biopsies?
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30321.
    PubMed        
    
    
25. FROEHNER M, Koch R, Thomas C
    Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30151.
    PubMed        
    
    
26. NORRIS JM, Carmona Echeverria LM, Bott SRJ, Brown LC, et al
    What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
    Eur Urol. 2020 May 1. pii: S0302-2838(20)30261.
    PubMed         Abstract available
    
    

    
    J Cell Physiol

27. FAN Y, Ou L, Fan J, Li L, et al
    PLCepsilon regulates metabolism and metastasis signaling via HIF-1alpha/MEK/ERK pathway in prostate cancer.
    J Cell Physiol. 2020 May 7. doi: 10.1002/jcp.29698.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

28. MARSHALL CH, Joshu CE
    Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer.
    J Clin Oncol. 2020 May 5:JCO2000791. doi: 10.1200/JCO.20.00791.
    PubMed        
    
    

    
    J Magn Reson Imaging

29. PADHANI AR, Schoots I, Villeirs G
    Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question.
    J Magn Reson Imaging. 2020 May 3. doi: 10.1002/jmri.27180.
    PubMed         Abstract available
    
    

    
    J Nucl Med

30. ZANG J, Liu Q, Sui H, Wang R, et al
    (177)Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242263. doi: 10.2967/jnumed.120.242263.
    PubMed         Abstract available
    
    
31. FENDLER WP, Ferdinandus J, Czernin J, Eiber M, et al
    Impact of (68)Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242180. doi: 10.2967/jnumed.120.242180.
    PubMed         Abstract available
    
    

    
    J Urol

32. MARKS LS, Natarajan S
    RE: Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naive Men.
    J Urol. 2020 May 4:101097JU0000000000001124. doi: 10.1097/JU.0000000000001124.
    PubMed        
    
    
33. GANDAGLIA G, Briganti A, Fossati N, Montorsi F, et al
    Re: Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 4:101097JU0000000000001122. doi: 10.1097/JU.0000000000001122.
    PubMed        
    
    

    
    Nat Rev Urol

34. LANGLAIS CS, Chan JM
    Opportunities and challenges for research on low-carbohydrate diets in prostate cancer.
    Nat Rev Urol. 2020 May 1. pii: 10.1038/s41585-020-0326.
    PubMed        
    
    
35. THOMA C
    PSMA PET-CT outperforms conventional imaging in high-risk prostate cancer.
    Nat Rev Urol. 2020 May 5. pii: 10.1038/s41585-020-0330.
    PubMed        
    
    
36. PHILIPPOU Y, Sjoberg H, Lamb AD, Camilleri P, et al
    Harnessing the potential of multimodal radiotherapy in prostate cancer.
    Nat Rev Urol. 2020 May 1. pii: 10.1038/s41585-020-0310.
    PubMed         Abstract available
    
    

    
    PLoS One

37. MURAKAMI Y, Magome T, Matsumoto K, Sato T, et al
    Fully automated dose prediction using generative adversarial networks in prostate cancer patients.
    PLoS One. 2020;15:e0232697.
    PubMed         Abstract available
    
    
38. 
    Retraction: Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties.
    PLoS One. 2020;15:e0233203.
    PubMed        
    
    
39. NGO D, Baumgartner R, Mt-Isa S, Feng D, et al
    Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    PLoS One. 2020;15:e0229336.
    PubMed         Abstract available
    
    

    
    Prostate

40. OJALILL M, Virtanen N, Rappu P, Siljamaki E, et al
    Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins.
    Prostate. 2020;80:715-726.
    PubMed         Abstract available
    
    
41. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study.
    Prostate. 2020 May 5. doi: 10.1002/pros.23991.
    PubMed         Abstract available
    
    
42. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2020;80:727.
    PubMed        
    
    

    
    Radiology

43. PADHANI AR, Petralia G
    Radiologists Should Integrate Clinical Risk Factors with MRI Findings for Meaningful Prostate Cancer Staging.
    Radiology. 2020 May 5:201082. doi: 10.1148/radiol.2020201082.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: